The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study: Frontiers in Genetics

M. Neri, R. Rossi, C. Trabanelli, A. Mauro, R. Selvatici, M.S. Falzarano, N. Spedicato, A. Margutti, P. Rimessi, F. Fortunato, M. Fabris, F. Gualandi, G. Comi, S. Tedeschi, M. Seia, C. Fiorillo, M. Traverso, C. Bruno, E. Giardina, M.R. PiemonteseG. Merla, M. Cau, M. Marica, C. Scuderi, E. Borgione, A. Tessa, G. Astrea, F.M. Santorelli, L. Merlini, M. Mora, P. Bernasconi, S. Gibertini, V. Sansone, T. Mongini, A. Berardinelli, A. Pini, R. Liguori, M. Filosto, S. Messina, G. Vita, A. Toscano, M. Pane, S. Servidei, E. Pegoraro, L. Bello, L. Travaglini, E. Bertini, A. D'Amico, M. Ergoli, E. Mercuri

Research output: Contribution to journalArticlepeer-review

Abstract

Dystrophinopathies are inherited diseases caused by mutations in the dystrophin (DMD) gene for which testing is mandatory for genetic diagnosis, reproductive choices and eligibility for personalized trials. We genotyped the DMD gene in our Italian cohort of 1902 patients (BMD n = 740, 39%; DMD n =1162, 61%) within a nationwide study involving 11 diagnostic centers in a 10-year window (2008–2017). In DMD patients, we found deletions in 57%, duplications in 11% and small mutations in 32%. In BMD, we found deletions in 78%, duplications in 9% and small mutations in 13%. In BMD, there are a higher number of deletions, and small mutations are more frequent than duplications. Among small mutations that are generally frequent in both phenotypes, 44% of DMD and 36% of BMD are nonsense, thus, eligible for stop codon read-through therapy; 63% of all out-of-frame deletions are eligible for single exon skipping. Patients were also assigned to Italian regions and showed interesting regional differences in mutation distribution. The full genetic characterization in this large, nationwide cohort has allowed us to draw several correlations between DMD/BMD genotype landscapes and mutation frequency, mutation types, mutation locations along the gene, exon/intron architecture, and relevant protein domain, with effects on population genetic characteristics and new personalized therapies. © Copyright © 2020 Neri, Rossi, Trabanelli, Mauro, Selvatici, Falzarano, Spedicato, Margutti, Rimessi, Fortunato, Fabris, Gualandi, Comi, Tedeschi, Seia, Fiorillo, Traverso, Bruno, Giardina, Piemontese, Merla, Cau, Marica, Scuderi, Borgione, Tessa, Astrea, Santorelli, Merlini, Mora, Bernasconi, Gibertini, Sansone, Mongini, Berardinelli, Pini, Liguori, Filosto, Messina, Vita, Toscano, Vita, Pane, Servidei, Pegoraro, Bello, Travaglini, Bertini, D'Amico, Ergoli, Politano, Torella, Nigro, Mercuri and Ferlini.
Original languageEnglish
JournalFront. Genet.
Volume11
DOIs
Publication statusPublished - 2020

Keywords

  • dystrophin
  • exon skipping therapy
  • muscular dystrophy
  • nationwide study
  • read-through therapy
  • genomic DNA
  • Article
  • cohort analysis
  • dystrophinopathy
  • exon skipping
  • frameshift mutation
  • gene deletion
  • gene duplication
  • gene mutation
  • genetic trait
  • genotype
  • high throughput sequencing
  • human
  • Italy
  • major clinical study
  • missense mutation
  • nonsense mutation
  • phenotype
  • stop codon

Fingerprint

Dive into the research topics of 'The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study: Frontiers in Genetics'. Together they form a unique fingerprint.

Cite this